You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Request a contact

Stay informed

Live Chat

 Go to Close Top

Device

In the preference study with FPNS (Meltzer EO, et al. 2008) the overall incidence of AEs with FF was 2% or 3 events: dizziness, headache, nasal congestion. 3

Stays where it sprays 1

Avamys Spray Comparison video

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Ireland/MP4/avamys-spray-comparison-website-video.mp4

Watch a video comparison of Avamys spray viscosity versus 2 competitor INS's devices

How to use Avamys device video

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Ireland/MP4/how-to-use-avamys-device-video-for-patients.mp4

A step by step guide to preparation and use of the Avamys nasal spray device.

how to use device

How to use device

Download Now

how to use device pdf

How to use device

Order hard copies now

Avamys is preferred over MFNS* 45

  • Several perceived sensory attributes of FFNS were rated significantly superior to MFNS 4
  • FFNS may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence 4

Overall, significantly more patients preferred FFNS over MFNS, p<0.001 5

Patient preference 56%
Patient preference 32%

Avamys provides improved experience vs MFNS 5

Less drip down nose

Less drip down nose
or throat 5

(p<0.05 and p<0.001, respectively)

Less irritation

Less irritation 5

(p<0.001)

More soothing

More soothing 5

(p<0.05)

Overall 5 patients (2%) reported AEs with FFNS and 13 patients (4%) with MFNS. Few common AEs were reported: rhinorrhoea, nasal discomfort, cough. No severe safety issues were identified during the study. 5

*Multicentre, randomised, double-blind, cross-over study where patient (n=300) preferences were determined by using three questionnaires
(Overall Preference, Immediate Attributes and Delayed Attributes).
AE: Adverse event; AR: Allergic rhinitis; FFNS: Fluticasone furoate nasal spray; FPNS: Fluticasone propionate nasal spray; MFNS: Mometasone furoate nasal spray.

References:

  1. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3);313-321.
  2. Avamys SmPC available on medicines.ie last accessed February 2025 https://www.medicines.ie/medicines/avamys-27-5-micrograms-spray-nasal-spray-suspension-31374/spc
  3. Meltzer EO, Stahlman JE, Leflein J, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther. 2008;30(2):271-279.
  4. Yonezaki M, Akiyama K, Karaki M, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx. 2016;43(3):292-297.
  5. Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol. 2016;7(4):e183–e192.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Avamys is a registered trademark of the GlaxoSmithKline group of companies